Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Merkel

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
The Journal of Pathology|March 31, 2015
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocationOlaf Merkel, Frank Hamacher, Robert Griessl, et al.
Leukemia|November 28, 2020
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphomaCosimo Lobello, Boris Tichy, Vojtech Bystry, et al.
Blood|November 1, 2014
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphomaAndre Weilemann, Michael Grau, Tabea Erdmann, et al.
Nature Communications|January 13, 2016
Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egressTim I M Malcolm, Patrick Villarese, Camilla J Fairbairn, et al.
Blood|October 4, 2017
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemiaBernd Boidol, Christoph Kornauth, Emiel van der Kouwe, et al.
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
Nature Communications|April 23, 2024
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastomaPerla Pucci, Liam C Lee, Miaojun Han, et al.
Oncotarget|June 17, 2015
AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasisJino Park, Michaela Schlederer, Martin Schreiber, et al.
Nature Communications|November 30, 2019
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN statusRicky M Trigg, Liam C Lee, Nina Prokoph, et al.
The British Journal of Dermatology|March 4, 2025
Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomasMariantonia Costanza, Catello Giordano, Ann-Christin von Brünneck, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
The Journal of Pathology|March 31, 2015
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocationOlaf Merkel, Frank Hamacher, Robert Griessl, et al.
Leukemia|November 28, 2020
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphomaCosimo Lobello, Boris Tichy, Vojtech Bystry, et al.
Blood|November 1, 2014
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphomaAndre Weilemann, Michael Grau, Tabea Erdmann, et al.
Nature Communications|January 13, 2016
Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egressTim I M Malcolm, Patrick Villarese, Camilla J Fairbairn, et al.
Blood|October 4, 2017
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemiaBernd Boidol, Christoph Kornauth, Emiel van der Kouwe, et al.
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
Nature Communications|April 23, 2024
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastomaPerla Pucci, Liam C Lee, Miaojun Han, et al.
Oncotarget|June 17, 2015
AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasisJino Park, Michaela Schlederer, Martin Schreiber, et al.
Nature Communications|November 30, 2019
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN statusRicky M Trigg, Liam C Lee, Nina Prokoph, et al.
The British Journal of Dermatology|March 4, 2025
Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomasMariantonia Costanza, Catello Giordano, Ann-Christin von Brünneck, et al.
Pageof 6